550 related articles for article (PubMed ID: 29572567)
1. Anti-Trichomonas vaginalis activity of ursolic acid derivative: a promising alternative.
Bitencourt FG; de Brum Vieira P; Meirelles LC; Rigo GV; da Silva EF; Gnoatto SCB; Tasca T
Parasitol Res; 2018 May; 117(5):1573-1580. PubMed ID: 29572567
[TBL] [Abstract][Full Text] [Related]
2. Anti-Trichomonas vaginalis activity from triterpenoid derivatives.
Innocente AM; Vieira Pde B; Frasson AP; Casanova BB; Gosmann G; Gnoatto SC; Tasca T
Parasitol Res; 2014 Aug; 113(8):2933-40. PubMed ID: 24880238
[TBL] [Abstract][Full Text] [Related]
3. 20S Proteasome as a Drug Target in Trichomonas vaginalis.
O'Donoghue AJ; Bibo-Verdugo B; Miyamoto Y; Wang SC; Yang JZ; Zuill DE; Matsuka S; Jiang Z; Almaliti J; Caffrey CR; Gerwick WH; Eckmann L
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451503
[TBL] [Abstract][Full Text] [Related]
4. Novel metronidazole-chalcone conjugates with potential to counter drug resistance in Trichomonas vaginalis.
Anthwal A; Rajesh UC; Rawat MS; Kushwaha B; Maikhuri JP; Sharma VL; Gupta G; Rawat DS
Eur J Med Chem; 2014 May; 79():89-94. PubMed ID: 24727243
[TBL] [Abstract][Full Text] [Related]
5. Anti-Trichomonas vaginalis activity of betulinic acid derivatives.
Hübner DPG; de Brum Vieira P; Frasson AP; Menezes CB; Senger FR; Santos da Silva GN; Baggio Gnoatto SC; Tasca T
Biomed Pharmacother; 2016 Dec; 84():476-484. PubMed ID: 27685791
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of netropsin dihydrochloride against the viability, cytopathogenicity and hemolytic activity of Trichomonas vaginalis clinical isolates.
Abou Gamra MM; Kamel HH; Ezz Eldin HM; Taha Zahran FM
J Infect Chemother; 2019 Dec; 25(12):955-964. PubMed ID: 31189504
[TBL] [Abstract][Full Text] [Related]
7. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.
Cudmore SL; Delgaty KL; Hayward-McClelland SF; Petrin DP; Garber GE
Clin Microbiol Rev; 2004 Oct; 17(4):783-93, table of contents. PubMed ID: 15489348
[TBL] [Abstract][Full Text] [Related]
8. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.
Seña AC; Bachmann LH; Hobbs MM
Expert Rev Anti Infect Ther; 2014 Jun; 12(6):673-85. PubMed ID: 24555561
[TBL] [Abstract][Full Text] [Related]
9. [Investigation of in vitro metronidazole resistance in the clinical isolates of Trichomonas vaginalis].
Ertabaklar H; Yaman Karadam S; Malatyalı E; Ertuğ S
Mikrobiyol Bul; 2016 Oct; 50(4):552-558. PubMed ID: 28124960
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of amixicile against T. vaginalis from clinical isolates.
Jain E; Zaenker EI; Hoffman PS; Warren CA
Parasitol Res; 2022 Aug; 121(8):2453-2455. PubMed ID: 35676563
[TBL] [Abstract][Full Text] [Related]
11. Anti-Trichomonas vaginalis activity of 1,10-phenanthroline-5,6-dione-based metallodrugs and synergistic effect with metronidazole.
Vargas Rigo G; Petro-Silveira B; Devereux M; McCann M; Souza Dos Santos AL; Tasca T
Parasitology; 2019 Aug; 146(9):1179-1183. PubMed ID: 30207253
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro cytotoxic effects of ornidazole, metronidazole and ciprofloxacin against Trichomonas vaginalis trophozoites.
Inceboz T; Inceboz U; Ozturk S
J Chemother; 2004 Oct; 16(5):459-62. PubMed ID: 15565912
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: case reports of three patients.
Hager WD
Sex Transm Dis; 2004 Jun; 31(6):343-5. PubMed ID: 15167642
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.
Wright JM; Dunn LA; Kazimierczuk Z; Burgess AG; Krauer KG; Upcroft P; Upcroft JA
Parasitol Res; 2010 Sep; 107(4):847-53. PubMed ID: 20532912
[TBL] [Abstract][Full Text] [Related]
15. Distribution of genotypes in relation to metronidazole susceptibility patterns in Trichomonas vaginalis isolated from South African pregnant women.
Mabaso N; Abbai N
Parasitol Res; 2021 Jun; 120(6):2233-2241. PubMed ID: 34002261
[TBL] [Abstract][Full Text] [Related]
16. Setting a colorimetric assay with MTT for assessment of trichomonicidal activity.
Sariego I; Monzote L; Rojas L
Curr Clin Pharmacol; 2014; 9(3):283-7. PubMed ID: 23173972
[TBL] [Abstract][Full Text] [Related]
17. Premature with trichomoniasis: report of one case.
Wang JJ; Yeung LK; Sun LC; Sy LB; Leu FJ
Acta Paediatr Taiwan; 2005; 46(4):219-21. PubMed ID: 16381336
[TBL] [Abstract][Full Text] [Related]
18. Management of metronidazole-resistant Trichomonas vaginalis--a new approach.
Mammen-Tobin A; Wilson JD
Int J STD AIDS; 2005 Jul; 16(7):488-90. PubMed ID: 16004628
[TBL] [Abstract][Full Text] [Related]
19. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
[TBL] [Abstract][Full Text] [Related]
20. Modulation of peptidases by 2,4-diamine-quinazoline derivative induces cell death in the amitochondriate parasite Trichomonas vaginalis.
Weber JI; Rigo GV; Rocha DA; Fortes IS; Seixas A; de Andrade SF; Tasca T
Biomed Pharmacother; 2021 Jul; 139():111611. PubMed ID: 34243597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
